IL33 and melanoma: It should be noted, however, that the expression of IL-33 and SIGLEC8 has been found to demonstrate different survival prognosis in diverse types of cancer, with better survival outcomes in melanoma patients but not in those with pancreatic adenocarcinoma and lung squamous cell carcinoma (60).